Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Antimicrob Agents Chemother
; 60(3): 1899-901, 2015 Dec 28.
Article
em En
| MEDLINE
| ID: mdl-26711770
ABSTRACT
Extended-infusion ceftolozane-tazobactam treatment at 1.5 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa in a critically ill patient on continuous venovenous hemofiltration. Serum drug concentrations were measured at 1, 4, 5, 6, and 8 h after the start of infusion. Prefilter levels of ceftolozane produced a maximum concentration of drug (Cmax) of 38.57 µg/ml, concentration at the end of the dosing interval (Cmin) of 31.63 µg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284.38 µg · h/ml, and a half-life (t1/2) of 30.7 h. The concentrations were eight times the susceptibility breakpoint for the entire dosing interval.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pseudomonas aeruginosa
/
Infecções por Pseudomonas
/
Cefalosporinas
/
Ácido Penicilânico
/
Antibacterianos
Tipo de estudo:
Observational_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Antimicrob Agents Chemother
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Estados Unidos